drugset / Trial / NCT02278302

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers

NCT02278302

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate whether psychomotor performance which is necessary for safety driving a car or operating machinery and safely participating in daily life is changed by Aggrenox®. Also to investigate whether Aggrenox® impairs performance in combination with alcohol more than alcohol alone. Derived from this: Statement on whether a warning for drivers is necessary

Timeline

Start
1999-08
Primary completion
2000-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 25 mg
Subject Dipyridamole Other / unclassified 200 mg

Indications

No indication recorded.